AU2003258816B2 - Novel aryl-{4-halo-4-[(heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments - Google Patents
Novel aryl-{4-halo-4-[(heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments Download PDFInfo
- Publication number
- AU2003258816B2 AU2003258816B2 AU2003258816A AU2003258816A AU2003258816B2 AU 2003258816 B2 AU2003258816 B2 AU 2003258816B2 AU 2003258816 A AU2003258816 A AU 2003258816A AU 2003258816 A AU2003258816 A AU 2003258816A AU 2003258816 B2 AU2003258816 B2 AU 2003258816B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- methanone
- amino
- ylmethyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 16
- 239000003814 drug Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 21
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- 150000007524 organic acids Chemical class 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 235000005985 organic acids Nutrition 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 91
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 claims description 28
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- PTJQZFWLRCSHOS-UHFFFAOYSA-N [4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 PTJQZFWLRCSHOS-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- RCNYUDQCXUKYBA-UHFFFAOYSA-N (3,4-difluorophenyl)-[4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(F)C(F)=CC=2)CC1 RCNYUDQCXUKYBA-UHFFFAOYSA-N 0.000 claims 1
- NVTWGZZOUHDHMJ-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-chloro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(C)=CC=C1CNCC1(Cl)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 NVTWGZZOUHDHMJ-UHFFFAOYSA-N 0.000 claims 1
- ZYDDGLQBPMAFOI-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-[4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(F)C(Cl)=CC=2)CC1 ZYDDGLQBPMAFOI-UHFFFAOYSA-N 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- QFNPKPKDVHIBAU-UHFFFAOYSA-N [4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=CC(F)=CC=2)CC1 QFNPKPKDVHIBAU-UHFFFAOYSA-N 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 abstract description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 13
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 13
- XIWLINXCINBRDK-UHFFFAOYSA-N [6-(methoxymethoxymethyl)pyridin-3-yl]methanol Chemical compound COCOCC1=CC=C(CO)C=N1 XIWLINXCINBRDK-UHFFFAOYSA-N 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 150000003141 primary amines Chemical class 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- SARODJOLCPBJHK-UHFFFAOYSA-N 5-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=C(C=O)N=C1 SARODJOLCPBJHK-UHFFFAOYSA-N 0.000 description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- FQTYMPNTUHMTSE-UHFFFAOYSA-N 5-(fluoromethyl)-2-(methoxymethoxymethyl)pyridine Chemical compound COCOCC1=CC=C(CF)C=N1 FQTYMPNTUHMTSE-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000017911 HTR1A Human genes 0.000 description 6
- 101150015707 HTR1A gene Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- LLZMRNQIAVJCJO-UHFFFAOYSA-N ethyl 6-(methoxymethoxymethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(COCOC)N=C1 LLZMRNQIAVJCJO-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SVCRXGVDWDIMLL-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-hydroxypyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(O)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 SVCRXGVDWDIMLL-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 4
- 229960002495 buspirone Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002295 serotoninergic effect Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- GVORVQPNNSASDM-UHFFFAOYSA-N 3-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Cl GVORVQPNNSASDM-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NVNPOQMXLQHPES-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-phenylmethoxypyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC(F)(CNCC=2N=CC(OCC=3C=CC=CC=3)=CC=2)CC1 NVNPOQMXLQHPES-UHFFFAOYSA-N 0.000 description 2
- XPMHHHJWQFUFAU-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-fluoro-4-[[[5-(fluoromethyl)pyridin-2-yl]methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(CF)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 XPMHHHJWQFUFAU-UHFFFAOYSA-N 0.000 description 2
- XXDCLDJEBGLWOD-UHFFFAOYSA-N 5-(fluoromethyl)pyridine-2-carbaldehyde Chemical compound FCC1=CC=C(C=O)N=C1 XXDCLDJEBGLWOD-UHFFFAOYSA-N 0.000 description 2
- OBPDHHJZPOGJPO-UHFFFAOYSA-N 5-methylpyrimidine-2-carbaldehyde Chemical compound CC1=CN=C(C=O)N=C1 OBPDHHJZPOGJPO-UHFFFAOYSA-N 0.000 description 2
- OPKGSXZJDAALJL-UHFFFAOYSA-N 6-methylpyridazine-3-carbaldehyde Chemical compound CC1=CC=C(C=O)N=N1 OPKGSXZJDAALJL-UHFFFAOYSA-N 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- RDSGPHNFOMPILP-UHFFFAOYSA-N ethyl 6-(hydroxymethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(CO)N=C1 RDSGPHNFOMPILP-UHFFFAOYSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000003723 serotonin 1A agonist Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- UFXIRMVZNARBDL-UHFFFAOYSA-N trifluoro(morpholin-4-yl)-$l^{4}-sulfane Chemical compound FS(F)(F)N1CCOCC1 UFXIRMVZNARBDL-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- JMHGATOBRPWPBZ-UHFFFAOYSA-N 3-cyano-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(C#N)=C1 JMHGATOBRPWPBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- UJMUKBUTBFMXHE-UHFFFAOYSA-N 5-[4-(aminomethyl)-4-fluoropiperidine-1-carbonyl]-2-fluorobenzonitrile Chemical compound C1CC(CN)(F)CCN1C(=O)C1=CC=C(F)C(C#N)=C1 UJMUKBUTBFMXHE-UHFFFAOYSA-N 0.000 description 1
- YYLBDBOSXXSZQQ-UHFFFAOYSA-N 5-chloropyridine-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)N=C1 YYLBDBOSXXSZQQ-UHFFFAOYSA-N 0.000 description 1
- DMDMMMFMXWZSLM-UHFFFAOYSA-N 6-formylpyridine-3-carbonitrile Chemical compound O=CC1=CC=C(C#N)C=N1 DMDMMMFMXWZSLM-UHFFFAOYSA-N 0.000 description 1
- MBVKWGKPRADLAP-UHFFFAOYSA-N 6-methylpyridazine-3-carbonitrile Chemical compound CC1=CC=C(C#N)N=N1 MBVKWGKPRADLAP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- ZZJYIKPMDIWRSN-HWBMXIPRSA-N LSM-20934 Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@H]1CN1CC[C@](C(C)(C)C)(O)C[C@H]13 ZZJYIKPMDIWRSN-HWBMXIPRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JDXNGJOXFKNYAQ-UHFFFAOYSA-N [4-(aminomethyl)-4-chloropiperidin-1-yl]-(3-chloro-4-fluorophenyl)methanone Chemical compound C1CC(CN)(Cl)CCN1C(=O)C1=CC=C(F)C(Cl)=C1 JDXNGJOXFKNYAQ-UHFFFAOYSA-N 0.000 description 1
- JRCBEKJHIWDFAA-UHFFFAOYSA-N [4-(aminomethyl)-4-fluoropiperidin-1-yl]-(4-chloro-3-fluorophenyl)methanone Chemical compound C1CC(CN)(F)CCN1C(=O)C1=CC=C(Cl)C(F)=C1 JRCBEKJHIWDFAA-UHFFFAOYSA-N 0.000 description 1
- RELMGALDUYBFJF-UHFFFAOYSA-N [4-(aminomethyl)-4-fluoropiperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1CC(CN)(F)CCN1C(=O)C1=CC=C(F)C=C1 RELMGALDUYBFJF-UHFFFAOYSA-N 0.000 description 1
- ZOAZIQMWEBKCPC-UHFFFAOYSA-N [4-(aminomethyl)-4-fluoropiperidin-1-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C1CC(CN)(F)CCN1C(=O)C1=CC=CC(C(F)(F)F)=C1 ZOAZIQMWEBKCPC-UHFFFAOYSA-N 0.000 description 1
- BIJPUEBJPVFNFK-UHFFFAOYSA-N [5-(fluoromethyl)pyridin-2-yl]methanol Chemical compound OCC1=CC=C(CF)C=N1 BIJPUEBJPVFNFK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- PKZXLMVXBZICTF-UHFFFAOYSA-N befiradol Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 PKZXLMVXBZICTF-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229950006479 butaclamol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003138 primary alcohols Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR02/07470 | 2002-06-18 | ||
| FR0207470A FR2840900B1 (fr) | 2002-06-18 | 2002-06-18 | Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| PCT/FR2003/001873 WO2003106449A1 (fr) | 2002-06-18 | 2003-06-18 | Nouveaux derives d'aryl-{4-halogeno-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003258816A1 AU2003258816A1 (en) | 2003-12-31 |
| AU2003258816B2 true AU2003258816B2 (en) | 2008-08-21 |
Family
ID=29595331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003258816A Expired AU2003258816B2 (en) | 2002-06-18 | 2003-06-18 | Novel aryl-{4-halo-4-[(heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7547700B2 (enExample) |
| EP (1) | EP1539738B1 (enExample) |
| JP (1) | JP4699027B2 (enExample) |
| CN (1) | CN1308325C (enExample) |
| AT (1) | ATE424396T1 (enExample) |
| AU (1) | AU2003258816B2 (enExample) |
| BR (1) | BRPI0311976B8 (enExample) |
| CA (1) | CA2489723C (enExample) |
| DE (1) | DE60326468D1 (enExample) |
| ES (1) | ES2321927T3 (enExample) |
| FR (1) | FR2840900B1 (enExample) |
| MX (1) | MXPA05000024A (enExample) |
| WO (1) | WO2003106449A1 (enExample) |
| ZA (1) | ZA200500467B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2852244B1 (fr) | 2003-03-13 | 2007-09-07 | Pf Medicament | Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene |
| FR2891274B1 (fr) * | 2005-09-27 | 2007-11-23 | Pierre Fabre Medicament Sa | Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires. |
| US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| CA2724737A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| FR2946344B1 (fr) | 2009-06-05 | 2012-05-25 | Pf Medicament | Nouveaux derives d'aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl} methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| WO2018057576A1 (en) * | 2016-09-22 | 2018-03-29 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds |
| US11191758B2 (en) | 2017-07-20 | 2021-12-07 | Neurolixis | Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors |
| WO2023144166A1 (en) | 2022-01-26 | 2023-08-03 | Neurolixis | Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN169588B (enExample) * | 1986-10-07 | 1991-11-16 | Pfizer Hospital Prod | |
| FR2755967B1 (fr) * | 1996-11-21 | 1999-01-29 | Pf Medicament | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments |
| FR2784378B1 (fr) * | 1998-10-09 | 2000-12-29 | Pf Medicament | Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| FR2820743B1 (fr) * | 2001-02-09 | 2005-02-25 | Pf Medicament | Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine |
-
2002
- 2002-06-18 FR FR0207470A patent/FR2840900B1/fr not_active Expired - Lifetime
-
2003
- 2003-06-18 CA CA2489723A patent/CA2489723C/fr not_active Expired - Lifetime
- 2003-06-18 MX MXPA05000024A patent/MXPA05000024A/es active IP Right Grant
- 2003-06-18 US US10/518,394 patent/US7547700B2/en active Active
- 2003-06-18 AU AU2003258816A patent/AU2003258816B2/en not_active Expired
- 2003-06-18 CN CNB038186047A patent/CN1308325C/zh not_active Expired - Lifetime
- 2003-06-18 DE DE60326468T patent/DE60326468D1/de not_active Expired - Lifetime
- 2003-06-18 BR BRPI0311976A patent/BRPI0311976B8/pt not_active IP Right Cessation
- 2003-06-18 ES ES03760060T patent/ES2321927T3/es not_active Expired - Lifetime
- 2003-06-18 EP EP03760060A patent/EP1539738B1/fr not_active Expired - Lifetime
- 2003-06-18 WO PCT/FR2003/001873 patent/WO2003106449A1/fr not_active Ceased
- 2003-06-18 AT AT03760060T patent/ATE424396T1/de not_active IP Right Cessation
- 2003-06-18 JP JP2004513281A patent/JP4699027B2/ja not_active Expired - Lifetime
-
2005
- 2005-01-18 ZA ZA2005/00467A patent/ZA200500467B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2489723A1 (fr) | 2003-12-24 |
| HK1075452A1 (en) | 2005-12-16 |
| DE60326468D1 (de) | 2009-04-16 |
| ZA200500467B (en) | 2005-12-28 |
| JP4699027B2 (ja) | 2011-06-08 |
| ES2321927T3 (es) | 2009-06-15 |
| BRPI0311976B1 (pt) | 2015-08-18 |
| EP1539738B1 (fr) | 2009-03-04 |
| AU2003258816A1 (en) | 2003-12-31 |
| BR0311976A (pt) | 2005-03-29 |
| US7547700B2 (en) | 2009-06-16 |
| WO2003106449A1 (fr) | 2003-12-24 |
| CA2489723C (fr) | 2011-08-02 |
| CN1308325C (zh) | 2007-04-04 |
| EP1539738A1 (fr) | 2005-06-15 |
| US20060100244A1 (en) | 2006-05-11 |
| BRPI0311976B8 (pt) | 2021-05-25 |
| ATE424396T1 (de) | 2009-03-15 |
| CN1675194A (zh) | 2005-09-28 |
| WO2003106449A8 (fr) | 2005-02-17 |
| FR2840900A1 (fr) | 2003-12-19 |
| JP2005534668A (ja) | 2005-11-17 |
| FR2840900B1 (fr) | 2005-02-25 |
| MXPA05000024A (es) | 2005-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5685082B2 (ja) | オルメサルタンメドキソミルの調製または精製の方法 | |
| WO1997047601A1 (en) | Fused heterocyclic compounds and medicinal uses thereof | |
| EP1487801B1 (en) | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo¬d|azepine derivatives with 5-ht6 receptor affinity for the treatment of cns disorders | |
| CA2927182A1 (en) | Quinolinyl modulators of ror.gamma.t | |
| AU2003258816B2 (en) | Novel aryl-{4-halo-4-[(heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments | |
| NO309603B1 (no) | Fremgangsmåte til fremstilling av substituerte dibenz[b,f][1,4]-oksazepin-11(10H)oner | |
| CA2076146A1 (en) | Piperidine derivatives | |
| AU2021410119A1 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
| KR20010041341A (ko) | 벤질피페라지닐 및 벤질피페리디닐 에탄온 유도체, 이의제조 방법 및 도파민 ｄ４ 수용체 길항제로서의 이의 용도 | |
| US20040034036A1 (en) | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide | |
| JP2003509494A (ja) | ムスカリン拮抗薬 | |
| EP0793663A1 (en) | (thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides | |
| HU184059B (en) | Process for preparing new 1,2-benzothiazine-1,1-dioxyde derivatives and pharmaceutical sompositions containing such compounds | |
| WO1998030559A1 (en) | Process for the production of tetrazolylbenzopyrans | |
| EP2022790A1 (en) | A process for the preparation or purification of olmesartan medoxomil | |
| HK1075452B (en) | Novel aryl- 4-halo-4- heteroarylmethylamino)-methyl -piperidin-1-yl -methanone derivatives, methods for production and use thereof as medicaments | |
| ZA200102942B (en) | Aryl-{4-fluoro-4-[(2-pyrid-2-ylethylamino)methyl]-1-peperidyl}-methanone derivatives as 5-HT1 receptor agonists. | |
| MXPA97000418A (en) | (1h-indol-4-il) -piperidine or tetrahydropyridine ethylamines etilcarboxami | |
| JPS5832877A (ja) | 新規なピペリジン誘導体 | |
| HK1115875A (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| MXPA00012479A (en) | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | |
| HK1074439B (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| HK1074439A1 (en) | Quinoline derivatives and their use as 5-ht6 ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NOVEL ARYL- {4-HALO-4-[(HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |